Clinical Trial to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total Thyroidectomy

A Randomized, Single-blind, Multi-center, Phase III Clinical Trail to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total Thyroidectomy

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02940210

Enrollment

172

Registered

2016-10-20

Start date

2016-08-31

Completion date

Unknown

Last updated

2016-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Thyroidectomy (Scheduled)

Brief summary

A randomized, single-blind, multi-center, Phase III clinical trial to evaluate the efficacy and safety of adhesion barrier Mediclore versus no treatment in patients with total thyroidectomy

Interventions

DEVICEMediclore® (adhesion barrier)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Written informed consent * Male or female at least 20 years of age * Patients without clinically significant lab * Patients scheduled for thyroidectomy

Exclusion criteria

* Another clinical trials within 1 month * History of previous surgery on same position * Anticoagulant, general steroids within a week from surgery * Immunosuppression or autoimmune disease * General or local infection * Serious diseases (heart failure, renal failure, liver failure, uncontrolled hypertension, diabetes mellitus, coagulation deficiencies) * Incompatible medications * History of drug or alcohol abuse, mental disorder * Pregnant or lactating women and fertile women who is not using proper contraceptive method * History of esophagus diseases * Keloid symptoms

Design outcomes

Primary

Measure	Time frame
Adhesion incidence rate following 8 weeks	8 weeks

Countries

South Korea

Contacts

Primary ContactWan Huh

whuh408@daewoong.co.kr+82-2-550-8106

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026